[3] [4] In the Phase 2 trial published in the New England Journal of Medicine (2023), participants receiving retatrutide achieved substantial reductions in body weight over 24 weeks, with higher doses associated with mean weight losses of approximately 17% of body weight
Brett Osborn, a Florida neurologist and longevity expert, agreed that the availability of the first generic GLP-1 is "great news." The generics lower price point is particularly beneficial for people who have chronic conditions like diabetes, Osborn noted "where long-term medication use is necessary to prevent downrange effects like vascular disease, strokes and heart attacks , cancer, neurodegenerative diseases like Alzheimers, and obesity, the latter of which is also a gateway disease," he said
172,174 Thus, we concluded several key genes have been identified with significant associations with SUA levels
Contact Legacy Clinic today to schedule a structural assessment
Together, you can create a sustainable, healthy lifestyle that empowers you to thrive without the need for medication.
Yes, oral semaglutide is a prescription GLP-1 receptor agonist approved for type 2 diabetes
